TY - JOUR
T1 - Feasibility and operational performance of tuberculosis detection by loop-mediated isothermal amplification platform in decentralized settings
T2 - Results from a multicenter study
AU - Gray, Christen M.
AU - Katamba, Achilles
AU - Narang, Pratibha
AU - Giraldo, Jorge
AU - Zamudio, Carlos
AU - Joloba, Moses
AU - Narang, Rahul
AU - Paramasivan, C. N.
AU - Hillemann, Doris
AU - Nabeta, Pamela
AU - Amisano, Danielle
AU - Alland, David
AU - Cobelens, Frank
AU - Boehme, Catharina C.
N1 - Publisher Copyright:
Copyright © 2016 David et al.
PY - 2016/8
Y1 - 2016/8
N2 - Currently available nucleic acid amplification platforms for tuberculosis (TB) detection are not designed to be simple or inexpensive enough to implement in decentralized settings in countries with a high burden of disease. The loop-mediated isothermal amplification platform (LAMP) may change this. We conducted a study in adults with symptoms suggestive of TB in India, Uganda, and Peru to establish the feasibility of using TB-LAMP (Eiken Chemical Co.) in microscopy laboratories compared with using smear microscopy against a reference standard of solid and liquid cultures. Operational characteristics were evaluated as well. A total of 1,777 participants met the eligibility criteria and were included for analysis. Overall, TB-LAMP sensitivities among culture-positive samples were 97.2% (243/250; 95% confidence interval [CI], 94.3% to 98.2%) and 62.0% (88/142; 95% CI, 53.5% to 70.0%) for smear-positive and smear-negative TB, respectively, but varied widely by country and operator. Specificities ranged from 94.5% (446/472; 95% CI, 92.0% to 96.4%) to 98.0% (350/357; 95% CI, 96.0% to 99.2%) by country. A root cause analysis identified high temperatures, high humidity, and/or low reaction volumes as possible causes for false-positive results, as they may result in nonspecific amplification. The study was repeated in India with training focused on vulnerable steps and an updated protocol; 580 participants were included for analysis. Specificity in the repeat trial was 96.6% (515/533; 95% CI, 94.7% to 97.9%). To achieve acceptable performance of LAMP at the microscopy center level, significant training and infrastructure requirements are necessary.
AB - Currently available nucleic acid amplification platforms for tuberculosis (TB) detection are not designed to be simple or inexpensive enough to implement in decentralized settings in countries with a high burden of disease. The loop-mediated isothermal amplification platform (LAMP) may change this. We conducted a study in adults with symptoms suggestive of TB in India, Uganda, and Peru to establish the feasibility of using TB-LAMP (Eiken Chemical Co.) in microscopy laboratories compared with using smear microscopy against a reference standard of solid and liquid cultures. Operational characteristics were evaluated as well. A total of 1,777 participants met the eligibility criteria and were included for analysis. Overall, TB-LAMP sensitivities among culture-positive samples were 97.2% (243/250; 95% confidence interval [CI], 94.3% to 98.2%) and 62.0% (88/142; 95% CI, 53.5% to 70.0%) for smear-positive and smear-negative TB, respectively, but varied widely by country and operator. Specificities ranged from 94.5% (446/472; 95% CI, 92.0% to 96.4%) to 98.0% (350/357; 95% CI, 96.0% to 99.2%) by country. A root cause analysis identified high temperatures, high humidity, and/or low reaction volumes as possible causes for false-positive results, as they may result in nonspecific amplification. The study was repeated in India with training focused on vulnerable steps and an updated protocol; 580 participants were included for analysis. Specificity in the repeat trial was 96.6% (515/533; 95% CI, 94.7% to 97.9%). To achieve acceptable performance of LAMP at the microscopy center level, significant training and infrastructure requirements are necessary.
UR - http://www.scopus.com/inward/record.url?scp=84979642629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979642629&partnerID=8YFLogxK
U2 - 10.1128/JCM.03036-15
DO - 10.1128/JCM.03036-15
M3 - Article
C2 - 27194691
AN - SCOPUS:84979642629
SN - 0095-1137
VL - 54
SP - 1984
EP - 1991
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 8
ER -